Metabolomics Technology Applied to Non-Invasive Nash Biomarkers Research

News   May 17, 2010

 
Metabolomics Technology Applied to Non-Invasive Nash Biomarkers Research
 
 
 

RELATED ARTICLES

Lonza Expands Encapsulation and HPAPI Capabilities in North America

News

Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.

READ MORE

A Mystery Solved: "Protein Cluedo" Reveals Enzyme Secrets

News

Scientists have used biosensors to solve questions about protein production which might seem familiar to mystery board game enthusiasts.

READ MORE

Researchers Discover Key Link Between Mitochondria and Cocaine Addiction

News

Researchers were able to block response in mitochondria to cocaine.

READ MORE

 

Comments | 1 ADD COMMENT

Ana Aitawa | Oct 03, 2017

The global nonalcoholic steatohepatitis (NASH) treatment market is estimated to reach US$ 19.8 Billion in 2025, expanding at a CAGR of 10.0% from 2017 to 2025, mainly driven by expected approval of Aramchol, Elafibranor, Obeticholic acid, and Simtuzumab, and introduction of several new high-priced products. Moreover, combination therapies are likely to dominate the global market over the forecast period. Visit Nonalcoholic Steatohepatitis Treatment Market by Drug Type (Pioglitazone and Type 2 Diabetes Mellitus (T2DM) Medicines, Vitamin E, Others), Pipeline Analysis (Phase III Drugs - Aramchol (Arachidyl Amido Cholanoic Acid), Elafibranor (GFT505), Emricasan (IDN-6556, PF-03491390), Obeticholic Acid (OCA/Ocaliva), Simtuzumab (GS-6624), Others), and Phase I and II Drugs 2017-2025 at https://www.ihealthcareanalyst.com/global-nonalcoholic-steatohepatitis-treatment-market/


Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE